Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Chondrosarcoma: early-phase trial registry

7 of 12 indexed Chondrosarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 7 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Chondrosarcoma: 12 US clinical trials tracked, 7 recruiting.

Chondrosarcoma is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition chondrosarcoma

OPEN 7 | RECR 58% | LATE 0 | EARLY 8 | RANK #1429 | SPON 2

Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)

Chondrosarcoma (this)58%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Chondrosarcoma

Chondrosarcoma lists 7 open slots (58% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chondrosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chondrosarcoma is recruiting above its size-band peers.

    7 of 12 indexed trials (58.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Chondrosarcoma research.

    M.D. Anderson Cancer Center accounts for 2 of 12 trials (16.7%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical Chondrosarcoma enrolment sits around 72 participants.

    Median target enrolment is 72 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.

  4. Chondrosarcoma research is mostly interventional.

    9 interventional and 3 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 25

Open and recent trials

12 total, page 1 of 1

RECRUITING 400 participants

Long-Term Longitudinal QoL in Patients Undergoing EEA

Ohio State University

NCT04087902

RECRUITING 300 participants

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

Memorial Sloan Kettering Cancer Center

NCT03442465

RECRUITING NA 150 participants

A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning

Ricoh USA

NCT06387485

RECRUITING Phase 2 140 participants

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

EpicentRx

NCT04673942

RECRUITING 72 participants

Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

Mayo Clinic

NCT05033288

RECRUITING Phase 1 54 participants

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center

NCT05039801

RECRUITING Phase 2 44 participants

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Medical College of Wisconsin

NCT04040205

ACTIVE NOT RECRUITING Phase 1 200 participants

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

NCT04521686

ACTIVE NOT RECRUITING Phase 1 17 participants

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Mohammed Milhem

NCT03173976

ACTIVE NOT RECRUITING Phase 2 15 participants

Proton Beam Therapy for Chondrosarcoma

M.D. Anderson Cancer Center

NCT00496522

ACTIVE NOT RECRUITING Phase 2 6 participants

AG-120 in People With IDH1 Mutant Chondrosarcoma

Memorial Sloan Kettering Cancer Center

NCT04278781

COMPLETED Phase 2 20 participants

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Wake Forest University Health Sciences

NCT01553539

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5

Named interventions

Most-linked intervention names on Chondrosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

therapeutic angiotensin-(1-7) Drug
1 trials
Proton Beam Therapy Procedure
1 trials
LY3410738 Drug
1 trials
Zoledronic Acid Drug
1 trials
CT/MRI Diagnostic test
1 trials
3D Printed Anatomic Model Device
1 trials
AG-120 Drug
1 trials
AdAPT-001 Biological
1 trials

US sites by state

Facility locations filed on Chondrosarcoma trials. A trial with sites in several states counts in each.

Texas 5 trials
Ohio 4 trials
New York 3 trials
Florida 3 trials
California 3 trials
New Jersey 2 trials
Minnesota 2 trials
Maryland 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chondrosarcoma page

12 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chondrosarcoma condition card totals 12 registered trials; most-linked intervention therapeutic angiotensin-(1-7); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.